Download FREE Report Sample
Download Free sampleGlioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline.
Glioblastoma Multiforme Therapeutics Market contains market size and forecasts of Glioblastoma Multiforme (GBM) Therapeutics in Global, including the following market information:
Global Glioblastoma Multiforme (GBM) Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Glioblastoma Multiforme (GBM) Therapeutics market was valued at 564.1 million in 2021 and is projected to reach US$ 990.5 million by 2028, at a CAGR of 8.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ChemOthersapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Glioblastoma Multiforme (GBM) Therapeutics include Merck, Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceuticals and Teva Pharmaceutical and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Glioblastoma Multiforme (GBM) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Glioblastoma Multiforme (GBM) Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment Percentages, by Type, 2021 (%)
ChemOthersapy
Targeted Drug Therapy
Radiation Therapy
Global Glioblastoma Multiforme (GBM) Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Glioblastoma Multiforme (GBM) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Glioblastoma Multiforme (GBM) Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Glioblastoma Multiforme (GBM) Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical
Emcure Pharmaceuticals
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
